Last reviewed · How we verify
Cisplatin (DDP)
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription, thereby inducing cancer cell death.
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription, thereby inducing cancer cell death. Used for Metastatic testicular cancer, Metastatic ovarian cancer, Advanced bladder cancer.
At a glance
| Generic name | Cisplatin (DDP) |
|---|---|
| Also known as | Cisplatin Injection |
| Sponsor | Sun Yat-sen University |
| Drug class | Platinum-based alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which distort the DNA helix and block DNA synthesis and repair mechanisms. This leads to apoptosis in rapidly dividing cancer cells. The drug is non-cell-cycle specific but most effective against cells in S and G2 phases.
Approved indications
- Metastatic testicular cancer
- Metastatic ovarian cancer
- Advanced bladder cancer
- Head and neck cancer
- Non-small cell lung cancer
- Gastric cancer
Common side effects
- Nephrotoxicity
- Ototoxicity
- Nausea and vomiting
- Myelosuppression (thrombocytopenia)
- Myelosuppression (leukopenia)
- Peripheral neuropathy
- Anemia
- Electrolyte abnormalities (hypomagnesemia)
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin (DDP) CI brief — competitive landscape report
- Cisplatin (DDP) updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI